Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
With one of the scores, higher adherence to the EAT-Lancet diet was associated with a reduced risk of AD and all-cause dementia.
Why it matters
This study found that higher adherence to the EAT-Lancet diet was associated with reduced risk of Alzheimer's disease and all-cause dementia among APOE ε4 non-carriers, but no associations were observed among APOE ε4 carriers. The findings are observational and do not establish causation.
-
Among 322 participants (48.8% women; mean age 71.4 ± 6.4 years), moderate-to-severe OSA (apnea–hypopnea index [AHI] ≥ 15) was identified in 48.49%, despite the absence of prior diagnoses.
Why it matters
In a group at increased risk for dementia, moderate-to-severe sleep apnea was common but often undiagnosed, and subjective screening tools underestimated its severity. This suggests that better objective assessment of sleep apnea could help identify and treat a modifiable risk factor for dementia.
-
One factor accounted for 79.0% of the variance in the UCLALS3; it was perfectly invariant across genders but variant at the metric level across countries.
Why it matters
This study tested a short three-item loneliness scale in dementia caregivers and found it valid, with a cutoff score of 6.5 that may flag caregivers with major clinically relevant symptoms. The authors say more investigations are needed to confirm the scale works the same way across countries.
-
49/100
Of 164,508 eligible participants, 6605(4%) had cognitive testing scores consistent with MCI.
Why it matters
In this UK Biobank study, people with mild cognitive impairment had modestly higher healthcare costs and a much higher rate of later Alzheimer's disease dementia than those without MCI. The findings describe costs and diagnosis patterns, not any treatment or way to prevent dementia.
-
Preventing dementia and Alzheimer's disease (AD) is a global priority.
Why it matters
This narrative review examines how adherence and intensity are reported in multimodal lifestyle trials aimed at preventing cognitive decline, and proposes ways to standardize adherence reporting. It does not test whether these interventions prevent Alzheimer's disease, so it cannot show that they work.
-
A European Task Force has recently developed and published the concept and protocols for the setup of the innovative health offer of Brain Health Services for the secondary prevention of dementia and cognitive impairment (dBHS). dBHS are outpatient health care facilities where adult persons can find an assessment of their risk of developing cognitive impairment and dementia, have their risk level and contributing factors communicated using appropriate language supported by adequate communication tools, can decide to participate to programs for personalized risk reduction if at higher risk, and benefit from cognitive enhancement interventions.
Why it matters
This paper describes Brain Health Services, outpatient facilities for secondary prevention of cognitive impairment and dementia in Europe. It discusses opportunities, challenges and the business case for these services, which assess risk, communicate it and offer personalized risk reduction and cognitive enhancement.
-
Hypertension is known to be a risk factor for cardiovascular diseases, but its relationship with cognitive impairment and dementia is an emerging area of study.
Why it matters
This meta-analysis found that people with hypertension had a 38% higher risk score for cognitive impairment than those without it, with midlife hypertension having the strongest link to late-life dementia. It describes associations and proposed mechanisms, so it does not show that treating hypertension prevents dementia.
-
Thirty constitutive elements of ACP were identified (e.g., 'assess understanding of ACP').
Why it matters
This 33-country Delphi study reached consensus on 30 constitutive elements of advance care planning in dementia, recommending that it be offered around dementia diagnosis, that end-of-life issues be raised later, and that it be embedded in a nonprescriptive, individualized approach involving both the person with dementia and their families. It provides guidance for care planning, not for treating, curing or preventing Alzheimer's disease.
-
A significant improvement in mental flexibility and planning abilities was observed in both groups (as measured by the Zoo planning test), but no other neuropsychological tests showed improvement.
Why it matters
In this non-randomized study, older adults with subjective cognitive complaints who did computerized cognitive training remotely or in person showed high adherence and improvement only in mental flexibility and planning, with no improvement on other neuropsychological tests. The study suggests telehealth training is feasible and acceptable, but it was not designed to prove effectiveness.
-
Alzheimer's disease (AD) ranks among the leading causes of morbidity and mortality worldwide.
Why it matters
This analysis of Global Burden of Disease data describes the prevalence, deaths, and disability-adjusted life years from Alzheimer's disease and other dementias in the Middle East and North Africa from 1990 to 2021. It reports burden trends and does not test any treatment, cure, or prevention.
-
Dementia rates are projected to increase significantly by 2050, posing considerable challenges for healthcare systems worldwide.
Why it matters
Using electronic medical record data from 283 older adults, a support vector machine classified mild cognitive impairment with 69% accuracy and an AUC of 0.75, with predictors including history of myocardial infarction, vitamin D3 levels, and the IADL scale. This is an initial classification tool and does not treat, cure, or prevent Alzheimer's disease.
-
Dyslipidemia, characterized by abnormal blood lipid levels, is a major public health concern due to its association with atherosclerotic cardiovascular disease (ASCVD) and other cardiometabolic disorders.
Why it matters
This review is about nutrition and lifestyle for managing dyslipidemia and cardiometabolic risk, not about Alzheimer's disease. It reports that diets such as the Mediterranean diet can improve lipid profiles by reducing oxidative stress and low-grade inflammation, but it makes no claim about dementia.
-
49/100
A total of 199 general practitioners and 67 caregivers participated in the quantitative study.
Why it matters
This mixed method study identified broad categories of caregiver needs: awareness and early diagnosis, information and training, practical coordinated support, and psychological support, and highlighted areas for improvement in meeting these needs. It describes caregiver needs rather than testing any treatment, cure or prevention for Alzheimer's disease.
-
Enhancing CRC screening, early detection, and public health interventions can significantly reduce CRC-related mortality.
Why it matters
This review is about colorectal cancer epidemiology, risk factors and public health strategies, not Alzheimer's disease. It reports on CRC risk factors such as processed foods, obesity, alcohol and smoking, and on protective factors such as vitamin D, calcium and fermented foods, with no relevance to dementia.
-
During aging, there is a progressive impairment of immune cell function that triggers the production of pro-inflammatory cytokines causing the so-called “inflammaging”.
Why it matters
In this cohort of older people with cognitive decline and dementia, only interleukin-10, interleukin-1β, and neurofilament light chain were associated with the risk for Alzheimer's disease and mixed dementia after adjustment. The findings concern inflammatory markers and do not test any treatment, cure, or prevention.
-
On average, surveyed caregivers (n = 431) were 78.3 years, had 16 years of education, and were mainly White (88.5%).
Why it matters
This cross-sectional survey of 431 caregivers found that as dementia knowledge scores increased, caregivers were more likely to endorse comfort care and less likely to need further treatment preference discussions. It highlights the role of dementia-specific education in advance care planning discussions.
-
We observed that existing AI-assisted dietary assessment tools are integrated with mobile/web-based applications to provide a user-friendly interface.
Why it matters
This review describes artificial intelligence-assisted dietary assessment tools that could estimate food and nutrient intake in people with chronic conditions including dementia. It reports no tested treatment, cure, or prevention, and the authors say more studies are needed to evaluate these tools.
-
Cardiovascular disease risk factors begin in childhood and track into adulthood, increasing the possibility of impaired cardiometabolic health.
Why it matters
This consensus document presents an updated Mediterranean Lifestyle Pyramid for children and adolescents, emphasizing physical activity, adequate sleep, and emotional health alongside dietary patterns. It is a prevention tool for health professionals and teachers, not a study of Alzheimer's treatment or cure.
-
49/100
Due to the ageing population throughout the world, the rates of older adults suffering from dementia are increasing, requiring a closer look at this population.
Why it matters
This scoping review gathered literature on the repercussions of abuse of elderly people with dementia by their caregivers, listing risk factors such as advanced disease stage and financial cost of treatment. It addresses abuse and caregiving and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
All groups showed significantly increased brain-PAD, and the median (IQR) brain-PAD was 4.3 (5.4) years in MCI, 6.3 (6.2) years in AD, and 5.0 (6.5) years in DLB.
Why it matters
In this cross-sectional multicenter study, brain age was higher than chronological age in people with mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies, and higher brain age was associated with depression and apathy symptoms. Brain-age analysis may be useful as a biomarker for assessing neuropsychiatric symptoms, but this does not treat, cure, or prevent Alzheimer's disease.
-
Thirty-three studies were included. Over half were conducted in Western countries (n =20).
Why it matters
This scoping review of 33 studies found that inadequate knowledge of person-centred care, staffing shortages, time constraints, and low wages were the main barriers to implementing person-centred dementia care in long-term care facilities in Western and Asian countries. It addresses care delivery challenges, not treatment, cure or prevention of Alzheimer's disease.
-
High weighted DD scores (24-31p) at age 9 months were associated with 61% decreased odds of FA at age 18 months [OR (95% CI) = 0.39 0.18-0.88] compared with infants with the lowest DD scores (0-17p).
Why it matters
This study is about food allergy in infants, not Alzheimer's disease, so it gives no information on Alzheimer's treatment, cure or prevention. It found that a more diverse diet at age 9 months was associated with lower odds of food allergy at 18 months.
-
Examining the risk of clinically diagnosed dementia in older adults, our study found a 65% increased risk of Alzheimer's disease (AD) dementia in individuals with diabetes compared with those without.
Why it matters
This review of three cohort studies found a 65% increased risk of Alzheimer's disease dementia in people with diabetes compared with those without. It also found associations between insulin resistance and brain infarcts and Alzheimer's pathology, suggesting implications for preventing cognitive decline in people with diabetes.
-
49/100
Virtual data collection was highly feasible in both studies, successfully engaging participants in ADRD research, including those from underrepresented racial and ethnic groups.
Why it matters
This paper reports that virtual data collection was feasible and successfully engaged participants in Alzheimer's disease and related dementias research, including underrepresented groups. It addresses research methods and inclusion, not treating, curing, or preventing the disease.
-
Among a cohort of 118 006 individuals, the incident rate (IR) of dementia was 0.56/1000 person-years over a median follow-up period of 1.54 years among SGLT-2i users compared with 2.67/1000 person-years in DPP-4i users, over a median follow-up period of 1.79 years.
Why it matters
Comparing SGLT-2i users with DPP-4i users, the study found no conclusive evidence of an association between SGLT-2i use and incident dementia overall. A lower risk was seen in the subgroup aged 65 and older, but the authors state the primary findings do not allow a firm conclusion.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Perspectives of Former Caregivers of Black Older Adults Living With Dementia on Advance Care Planning
- Wine Intake in the Framework of a Mediterranean Diet and Chronic Non-Communicable Diseases: A Short Literature Review of the Last 5 Years
- Can the herpes zoster vaccination be a strategy against dementia?
- Nutrition and cognitive health: A life course approach
- Aging and Hearing Health: The Life-course Approach
- ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
- Disability in geriatric depression
- Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study
- Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study
- The Differential Diagnosis and Treatment of Atypical Parkinsonism